earnings
confidence high
sentiment positive
materiality 0.80
Petros Pharmaceuticals reports Q2 net sales of $4.2M, first positive adjusted EBITDA of $0.2M
Petros Pharmaceuticals, Inc.
2022-Q2 EPS reported
-$0.10
revenue$6,651,685
- Q2 net sales of $4.2M, up 68% from $2.5M in Q2 2021; net loss narrowed to $1.8M from $2.1M.
- First positive adjusted EBITDA of $0.2M, compared to negative $2.0M in prior-year period.
- Prescription Medicines segment (STENDRA) sales up 102% YoY to $3.3M; gross margin stable at 84%.
- Cash balance $13.3M as of June 30, 2022, down from $17.7M at March 31, 2022.
- Announced positive OTC label comprehension study for STENDRA and pursuit of 505(b)(2) pathway for H-100 for Peyronie's disease.